<DOC>
	<DOCNO>NCT00002096</DOCNO>
	<brief_summary>To determine whether pharmacokinetic drug interaction oral ganciclovir oral zidovudine ( AZT ) oral ganciclovir oral didanosine ( ddI ) . To determine whether concurrent administration probenecid affect pharmacokinetics oral ganciclovir . To obtain data short-term safety oral ganciclovir administer concurrently AZT , ddI , probenecid HIV-positive patient .</brief_summary>
	<brief_title>A Phase I Pharmacokinetic Study HIV-Positive Subjects Oral Ganciclovir Concomitant Antiretroviral Zidovudine Didanosine</brief_title>
	<detailed_description>Patients currently either AZT ddI receive ganciclovir therapy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Concomitant AZT ddI . Allowed : Probenecid . Aerosolized pentamidine . Patients must : Asymptomatic HIV infection . CMV seropositivity CMV culture positivity present time past . No history CMV disease ( e.g. , retinitis , colitis ) AIDSdefining illness . Treatment AZT ddI least 1 month prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Uncontrolled diarrhea ( three loose stools/day ) . Clinically significant gastrointestinal symptom include persistent nausea abdominal pain . AZT patient : Deficiency glucose6phosphate dehydrogenase . ddI patient : Grade 2 bad peripheral neuropathy . Concurrent Medication : Excluded : Combination antiretroviral therapy . GCSF GMCSF . Acyclovir . Amphotericin B. Amikacin . Captopril . Carbamazepine . Cimetidine . Cyclosporine . Glutethimide . Gentamicin . Griseofulvin . Ibuprofen . ImipenemCilastatin . Lithium . Methicillin . Methotrexate . Naproxen . Pentamidine ( Pentam 300 ) ( Aerosolized drug permit ) . Phenacetin . Phenobarbital . Phenytoin . Piroxicam . Ribavirin . Rifampin . Tobramycin . Vidarabine . Zalcitabine . Other investigational drug . Patients follow prior condition exclude : History hypersensitivity acyclovir ganciclovir . AZT patient : History gout , uric acid , kidney stone , peptic ulcer porphyria . ddI patient : History pancreatitis alcoholism , seizure within 6 month prior study entry prior need anticonvulsant therapy . Prior Medication : Excluded : Combination antiretroviral therapy within 1 month prior study entry . Required : AZT 500 mg/day least 1 month prior study entry ( 100 mg administer five time per day least 1 week prior study entry ) . OR ddI recommend dose least 1 month prior study entry ( 250 mg administer every 12 hour least 1 week prior study entry ) . History alcoholism ( ddI patient ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1993</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>